There is evidence for both similarity and distinction in the presentation and molecular characterization of schizophrenia and bipolar disorder. In this study, we characterized protein abnormalities in the dorsolateral prefrontal cortex in schizophrenia and bipolar disorder using two-dimensional gel electrophoresis. Tissue samples were obtained from 35 individuals with schizophrenia, 35 with bipolar disorder and 35 controls. Eleven protein spots in schizophrenia and 48 in bipolar disorder were found to be differentially expressed (P < 0.01) in comparison to controls, with 7 additional spots found to be altered in both diseases. Using mass spectrometry, 15 schizophrenia-associated proteins and 51 bipolar disorder-associated proteins were identified. The functional groups most affected included synaptic proteins (7 of the 15) in schizophrenia and metabolic or mitochondrial-associated proteins (25 of the 51) in bipolar disorder. Six of seven synaptic-associated proteins abnormally expressed in bipolar disorder were isoforms of the septin family, while two septin protein spots were also significantly differentially expressed in schizophrenia. This finding represented the largest number of abnormalities from one protein family. All septin protein spots were upregulated in disease in comparison to controls. This study provides further characterization of the synaptic pathology present in schizophrenia and of the metabolic dysfunction observed in bipolar disorder. In addition, our study has provided strong evidence implicating the septin protein family of proteins in psychiatric disorders for the first time.
Introduction
The dorsolateral prefrontal cortex (dlPFC) (Brodmann areas 9, 10, 42, 45 and 46) has primary functions in working memory, willed action and decision making. 1 Support for dysfunction in this brain region at the imaging, cellular and molecular level in schizophrenia [2] [3] [4] [5] and bipolar disorder [6] [7] [8] is very strong. To investigate these findings at the cellular and protein level, a large number of neuropathological studies investigating schizophrenia have focused on this brain region. Cytoarchitectural studies have found evidence for an increase in neuronal density, 9 decrease in neuronal size, 10, 11 reduced pyramidal neuron dendritic field 12, 13 and decreased dendritic spine density 14, 15 with similar reductions in neuronal size observed in BPD. 16 Efforts to determine the neurochemical and molecular basis for these cellular alterations have revealed abnormalities in neurotransmission, signal transduction, inhibitory interneuron function and glial cells. 17 In a review of 100 neurochemical markers assessed in multiple brain areas in the Stanley Foundation Brain Consortium, it was found that developmental/synaptic, GABAergic and markers involved in signal transduction were all reduced in the schizophrenia group in the prefrontal cortex. 18 Global gene and protein profiling studies are powerful methods to reveal molecular mechanisms of dysfunction and specific candidate genes/proteins, which were previously unknown or overlooked.
Several microarray investigations of mRNA expression levels in schizophrenia and control subjects have now been carried out using post-mortem tissue from the prefrontal cortex. [19] [20] [21] [22] [23] In the first study of this kind, many genes encoding for presynaptic proteins were found to be abnormally expressed. 23 Indeed, synaptic disturbance in schizophrenia is well described, involving both the pre-and postsynaptic machinery, and is considered a characteristic feature of this complex disorder. [24] [25] [26] [27] However, mRNA may not be the most reliable method to use in order to gain insight into the underlying pathophysiology of schizophrenia, where abnormalities in gene function may or may not affect downstream protein expression. 28, 29 To approach this issue, proteomic techniques have been used, on a complementary basis, to investigate the underlying molecular abnormalities in the cortex in schizophrenia. [30] [31] [32] [33] These studies have identified a number of abnormally expressed proteins, including those involved in oxidative stress and mitochondrial function.
It is possible that some of the findings of altered metabolism and mitochondrial function may be related to confounding factors present when working with post-mortem tissue such as brain pH and postmortem interval (PMI). 34 For example, genes relating to energy metabolism and proteolytic activities are decreased at low brain pH. 35 Given these findings, and those of others that have found significant alterations at the protein level with varying PMI times, 36, 37 high-throughput studies of protein and gene expression must take these post-mortem factors into consideration in their data analysis. 33 The aim of the present study was to further characterize differential protein expression in the cortical grey matter in post-mortem brain tissue taken from the dlPFC (Brodmann's area 9) of 105 patients from control, schizophrenia or bipolar patient groups using a non-hypothesis gel-based approach. This is the most extensive proteomic study of its type in psychiatric disorders to date, including the largest samples of schizophrenia and bipolar disorder subjects.
Materials and methods

Samples
Blocks of dlPFC grey matter from Brodmann area 9 (superior frontal gyrus) were obtained from the second Stanley Brain Collection (www.stanleyresearch.org). This sample consists of 105 subjects (35 controls, 35 schizophrenics and 35 bipolar disorder). Diagnoses were made according to the Diagnostic and Statistical Manual of Mental Disorders IV criteria. Detailed case summaries are provided on demographic, clinical and histological information (Table  1) . Due to missing demographic data including one case of CADASIL and additional technical problems (poor protein separation and matching with other gels), nine samples were removed from the final analysis; Table 1 provides the demographic information of the 96 cases included in the study. All brains underwent clinical neuropathological examination and none demonstrated evidence of neurodegenerative changes or other pathological lesions. Frozen tissue was available from one hemisphere of each brain, with approximately equal numbers sampled in a random manner. Investigators were blinded to group identity until after completion of the data collection stage.
Tissue dissection and protein solubilization A 100-150 mg portion of cortical grey matter was dissected from the fresh, frozen brain tissue of each of the 105 cases of dlPFC. Each sample was solubilized using a pestle in 1.5 ml Eppendorf tubes with 1 ml of solubilization buffer, a lysis buffer based on that originally used by O'Farrell, 38 containing 9.5 M urea, 2% (w/v) CHAPS, 0.8% (v/v) Pharmalyte, pH 3-10, 1% (w/v) DTT and 150 ml Mini Complete Protease Inhibitor Cocktail (Roche Molecular Biochemicals, Indianapolis, IN, USA), and centrifuged at 13 000 g at 20 1C for 5 min.
Separation of proteins by two-dimensional gel electrophoresis Two-dimensional gel electrophoresis was carried out as described previously. 33 Briefly, proteins were separated in the first dimension according to their pI values by isoelectric focusing using pH 4-7 18 cm immobilized pH gradient strips (GE Healthcare, Amersham, UK). Samples were diluted in rehydration buffer (8 M urea, 0.5% w/v CHAPS, 0.2% w/v DTT, 0.2% w/v Pharmalyte, pH 3-10) and a protein load of 100 mg for analytical gels and 400 mg for preparative gels was loaded onto the strips using in-gel rehydration. 39, 40 Immobilized pH gradient strips were left to rehydrate overnight and subsequently focused for 75 000 V h. Following isoelectric focusing, strips were equilibrated in 6 M urea containing 30% w/v glycerol, 2% (w/v) SDS and 0.01% (w/v) Bromophenol blue, with the addition of 1% (w/v) DTT for 15 min, followed by the same buffer without DTT, but with the addition of 4.8% (w/v) iodoacetamide for 15 min. 41 Second-dimension SDS-polyacrylamide gel electrophoresis was performed using 12% polyacrylamide gels run overnight at 20 mA per gel at 15 1C (Hoefer DALT system, GE Healthcare). Following electrophoresis, gels were fixed overnight in a methanol/acetic acid solution and visualized with the Owl Silver Stain kit (Insight Biotechnology, London, UK). For preparative gels, the PlusOne Silver Staining kit (Amersham Biosciences, Uppsala, Sweden) was used with modifications to allow subsequent use with mass spectrometric analysis. system Progenesis V2003.2 (Nonlinear Dynamics, Newcastle, UK). Following automatic and subsequent manual editing, warping and matching procedures, the normalized volume of each protein, an integration of optical density and area, was measured objectively as a percentage of the total volume of all the detected spots and the data exported for analysis.
Statistical analysis
The primary analysis was to detect proteins differing in expression between the control group and either the schizophrenia or bipolar disorder groups. Since brain pH, refrigerator interval, PMI and age are known to considerably influence protein expression in the brain, 36, 37 an analysis of covariance (ANCOVA) on normalized spot volumes was performed. Estimated differences between controls and schizophrenia or bipolar disorder were obtained from the model as differences in least squares means (linear contrasts). Prior to analysis, the data were log 10 transformed to reduce distributional skew and to improve the normal approximation for valid P-values. Significance testing was performed at the 1% level. All statistical tests were carried out using SAS V9.1 software.
Secondary analysis of the effects of each of the covariates included in the primary analysis was also carried out using ANCOVA. In the case of potential confounding variables, which covary with disease status, a secondary multivariate analysis (multiple regression analysis) was carried out excluding disease status from the model. The variables examined using this model were antipsychotic, mood stabilizer and antidepressant status at the time of death and lifetime alcohol abuse and fluphenazine equivalent dose.
To determine if our proteomic findings converged with mRNA data from the same brain regions (dlPFC), additional post hoc analyses were carried out using three of the microarray data sets (Study ID numbers 1, 3 and 7) from the same tissue that is available online from the www.stanleygenomics.org website. From the 100 probes, which corresponded to the proteins listed in Table 2 independent t-tests were carried out between the disease groups and controls.
Protein identification by liquid chromatography-tandem mass spectrometry All protein spots found to be significantly differentially expressed were subsequently cut from the preparative gels using a 1.5 mm pipette tip and placed in water. Spot plugs were destained and proteins were digested with trypsin as described previously. 42 All samples were run on a Finnigan LTQ mass spectrometer connected to a Surveyor chromatography system incorporating an auto-sampler. Tryptic peptides were resuspended in 0.1% formic acid and were separated by means of a modular CapaLC system (Finnigan) connected directly to the source of the LTQ. Each sample was loaded onto a Biobasic C18 Abbreviations: dlPFC, dorsolateral prefrontal cortex; PMI, post-mortem interval; 2D, two dimensional. Mean scores are given with standard deviations. Disease group details were found to be significantly different from the control group following independent t-test (disease versus control groups). *P < 0.05; **P < 0.01. Relationships between potential confounding factors and protein expression were explored for all significant proteins using ANCOVA. Proteins found to be significantly expressed in the same tissue at the transcript level in three of the six data sets available at www.stanleygenomics.org are also reported. Data relating to direction of change in these transcript studies were not available publicly on the website and are therefore not presented here. SMRI array database study ID numbers 1, 3 and 7 refer to those listed on the website. Proteins that were found to be predicted by age (*), brain pH (^), post-mortem interval ( þ ), refridgerator interval (#), antipsychotic dose (mg per lifetime) (D) and either antidepressant (K) or antipsychotic (1) medication treatment at the time of death with significance P < 0.01 are listed in the final column. Picofrit column (100 mm length, 75 mm ID) at a flow rate of 30 nl min À1 . The samples were then eluted from the C18 Picofrit column by an increasing acetonitrile gradient. The mass spectrometer was operated in positive ion mode with a capillary temperature of 200 1C, a capillary voltage of 46 V, a tube lens voltage of 140 V and with a potential of 1800 V applied to the frit. All data were acquired with the mass spectrometer operating in the automatic data-dependent switching mode. A zoom scan was performed on the five most intense ions to determine charge state prior to tandem mass spectrometry analysis.
Database searching
The raw mass spectral data were analysed using Proline, a proteomics analysis platform. Thermo RAW files were converted into mzXML format. X! Tandem release 2005.02.01 was used to analyse these files with a static iodoacetamide modification, with Uniprot/SwissProt release 7.6 used as the FASTA search database. The results were stored in a MySQL database and were interrogated using Proline's webbased proteomics toolset.
Further investigation of septin abnormalities
Changes in septin 5 expression were remarkable, with two protein spots significantly increased in expression in both disorders and a further form of the same protein found to be increased in bipolar disorder when compared to control cases. To confirm the presence of multiple protein spots of septin 5 on the two-dimensional (2D) gel and to further investigate septin 5 protein spots, a 2D blot was carried out. A 2D gel (100 mg protein load) was run as described previously and transferred onto Hybond nitrocellulose membranes (GE Healthcare) using a semi-dry apparatus (GE Healthcare) for 2 h at 0.8 mA per cm 2 . The membrane was subsequently blocked with 5% non-fat dried milk (NFDM) in phosphate-buffered saline (PBS) for 1 h. The septin 5 antibody (Chemicon, CA, USA; MAB5358) was applied at 1/1000 in 5% NFDM/PBS and incubated overnight at 4 1C. Following two washes in 5% NFDM/PBS, the horseradish peroxidase-conjugated anti-mouse secondary antibody (Dako, Glostrup, Denmark) was added at a concentration of 1/2000 and left for 1 h at room temperature. Two further washes in 5% NFDM/PBS and then PBS were carried out before incubating for 5 min in Supersignal chemiluminescent substrate (Pierce, IL, USA). Blots were then exposed to X-ray film and developed.
Results
2D gel electrophoresis
A total of 1944 individual spots were visualized across the group of 105 dlPFC gels (pH 4-7) (Figure 1 ). Statistical analyses were carried out on all of these spots and subsequently 101 differentially expressed significant (P < 0.01) spots (20 schizophrenia, 69 bipolar disorder, 12 both disorders) were identified with ANCOVA (correcting for age, brain pH, refrigerator interval and PMI).
Of these 101 spots, 35 were excluded because they could not be visually confirmed or were not present in the preparative gel used for identification of each protein spot. Thus a total of 66 spots of interest were visually confirmed and available for identification by mass spectrometry. Of these, 11 were in the schizophrenia group, 48 in the bipolar disorder group and 7 spots were abnormally expressed in both disorders in comparison to control patients.
Mass spectrometry
Of the 66 protein spots visually confirmed as being differentially expressed protein spots in the schizophrenia or bipolar disease groups, 63 proteins were identified using liquid chromatography-tandem mass spectrometry (see Figure 1) . Nine proteins were identified that were found to be differentially expressed in schizophrenia, 45 proteins were identified that were significantly associated with bipolar disorder and 6 proteins were identified that were significant in both disorders.
The identities of these protein spots, their fold change alteration in volume density on the 2D gel, the theoretical pI and MW and the peptide sequences matched for each protein are shown in Table 2 . The proteins are listed alphabetically with their functional ontology and any predictive relationship with any of the major confounding factors evaluated. Table 2 .
Functional analysis of protein findings
To evaluate the differences in overall protein expression in both schizophrenia and bipolar disorder, proteins differentially expressed in both disorders were grouped according to functional ontology. This grouping was based on literature searching, information provided for each protein at www.ebi.ac.uk/ego, www.expasy.org, http://harvester.embl.de/html/protein_lists.html and www.hprd.org. Figure 2 illustrates the broad distribution of protein expression abnormality seen in each group and the differences between them.
Confirmation of protein changes
Two of the six proteins found to be differentially expressed in both schizophrenia and bipolar disorder were forms of septin 5 (P < 0.01) (see Figure 1 and Table 2 ). Additionally, another form of septin 5 and three further septin family proteins were found to be significantly increased in bipolar disorder (P < 0.01; septin 6 and two forms of septin 11). To further examine the forms of septin 5 proteins observed on the 2D gels we performed a 2D western blot using an antibody-specific for septin 5. Five spots were identified, which could result from differences in post-translational modifications, possibly including phosphorylations. Figure 3 shows all five septin 5 protein spots detected by the 2D western blot, and identifies the positions of the three septin 5 spots that were first found to be abnormal in the primary analysis (spots 4, 5 and 42). We then went back to the primary analysis and re-examined the data for the two newly identified spots (spots 50 and 51).
As can be seen from Table 3 , there is increased expression of all five forms of septin 5 in bipolar disorder in comparison to controls (at P < 0.05). For septin 5 there are also three forms, which are significantly increased in expression in the schizophrenia sample. Septin 11 is upregulated in two forms in bipolar disorder, with one of these increased in schizophrenia. Septin 6 is altered only in bipolar disorder where it shows a 2.3-fold increased expression. Post hoc ANCOVA analysis of these septin family proteins combined showed them to be highly significant both for bipolar disorder (P < 0.0001) and schizophrenia (P < 0.0001).
Findings at the transcript level
Out of 100 probes (corresponding to 23 out of the 52 proteins reported in Table 2 ) 31 were significantly abnormally expressed at the transcript level (P < 0.05) in the Stanley Medical Research Institute array database as well as at the protein level. The results from these analyses are listed in a separate column in Table 2 . Figure 2 Visual representation of the cell functions affected in schizophrenia and bipolar disorder in the dorsolateral prefrontal cortex grey matter. Each protein found to be differentially expressed and identified using mass spectrometry was grouped into one or more ontological categories. Up-and downregulation is indicated by its position in either minus or plus on the graphs axis. Table 3 for fold differences between disease and control groups for these spots (corresponding numbers are used).
Discussion
This study investigated the global protein expression levels of 1944 protein spots found in the pH range 4-7 in 97 2D gel images of human post-mortem brain tissue taken from schizophrenia, bipolar disorder and control cases. This is the largest proteomic study to date that has investigated dlPFC grey matter in both schizophrenia and bipolar disorder. Our findings demonstrate novel and robust alterations in the septin family of proteins in both disorders. The findings also extend and elaborate on the evidence already implicating synaptic and metabolic pathology in these disorders.
Functionally grouping the proteins revealed relatively different disease profiles in schizophrenia and bipolar disorder (see Figure 2) . Functionally, 7 of 15 of the proteins found to be significantly differentially expressed in schizophrenia are associated with synaptic function and 4 of 15 with metabolic or mitochondrial function. A smaller number of proteins also fell into the categories of protein synthesis, protein folding, cytoskeleton and brain development. In marked contrast, in bipolar disorder, 25 of 51 of the significantly differentially expressed proteins were associated with metabolic and mitochondrial function, 9 of 51 cytoskeletal and 6 of 51 synaptic associated. Other categories included proteolysis, protein folding, protein synthesis, brain development, cell signaling, cell division and blood regulation. It is also of interest to note that the majority of proteins abnormally expressed in bipolar disorder were upregulated rather than downregulated in comparison with controls. Protein expression changes were more prominent in bipolar disorder (55 differentially expressed protein spots) than in schizophrenia (18 differentially expressed protein spots), although seven of these were differentially expressed in both. The clearest point of distinction was a predominance of metabolic-associated protein changes in bipolar disorder, and of synaptic-associated protein changes in schizophrenia. The following sections will focus on the possible roles of these proteins in synaptic and metabolic dysfunction in schizophrenia and bipolar disorder.
Evidence for synaptic dysfunction in psychiatric disorders Expression changes in many synaptic-associated proteins such as synaptophysin, complexin I and II, synaptosomal-associated protein (SNAP)-25 and syntaxin (for example Eastwood et al., 43 Sawada et al., 44 Owen et al. 45 and Frankle et al. 46 ) have been found in schizophrenia. In addition, these protein changes are in keeping with synaptic-associated roles for many of the recently described candidate genes for schizophrenia. 47 Consequently, our finding of substantial synaptic-associated protein pathology in schizophrenia is in keeping with these previous findings. Additionally, we have been able to extend the literature by increasing our knowledge of the identity of some of the synaptic-associated proteins involved in this disease process. In the present study, the expression of five protein spots that are associated with synaptic function were increased (two forms of septin 5 and dihydropyrimidinase-related protein-3 (DRP-3), one form of dynamin I (DYN-I)) in schizophrenia and two proteins were decreased (protein kinase C and casein kinase in neurons 1 (PACSIN 1) and neurofilament triplet L). Synaptic dysfunction in bipolar disorder was also implicated and is consistent with the literature. [48] [49] [50] [51] In bipolar disorder, six proteins with synaptic-associated function were found to be increased (three forms of septin 5 and septin 6 and two forms of DRP-3).
The majority of the synaptic proteins found to be altered in the schizophrenia group in the present study were increased and not decreased as shown in Figure 2 . However, this apparent increase in synapticassociated protein expression is largely due to the number of septin protein changes in schizophrenia, all of which were increased (see Table 3 ). Otherwise, we found both increases and decreases in expression of synaptic-associated proteins (septin 5, DRP-3 and dynamin were increased and neurofilament triplet L (NF-L) and PACSIN 1 were decreased). The first two of these proteins are implicated in the present study for the first time in schizophrenia, whereas DYN-I, which is involved in vesicle endocytosis, has been found to be upregulated in schizophrenia in two previous proteomic studies. 31, 32 NF-L expression has previously been reported to be reduced in schizophrenia.
The proteins associated with synaptic function that were found to be most significantly altered in both disorders were two forms of DRP-3, which were found to have increased expression in schizophrenia and bipolar disorder (P < 0.0002; 1.5-to 1.9-fold change). This protein (also known as Ulip6/Unc-33like protein/CRMP5) was first characterized in 1996 and found to have significant homology to Unc-33, a protein important for neuronal development and neurite outgrowth. 52 Since then, the protein has been shown to interact with an integral membrane glycine transporter located in axonal terminals and found to be localized to synaptic regions of rat neurons. 53 Given this evidence for a role for DRP-3 in synaptic function, it has been suggested that this protein may participate in the regulation of glycine transporter 2 recycling, a process important in the modulation of neurotransmitter reuptake at the nerve terminals. 53 DRP-3 is also involved in glutamatergic function, and a degraded form of the protein occurs in the presence of glutamate excitotoxicity (N-methyl-D-aspartate (NMDA)) and oxidative stress. 54 The functional role of DRP-3 with the glutamatergic system is yet to be revealed, but given the evidence for glutamatergic dysfunction in schizophrenia 47 it is interesting that an increase in DRP-3 could be indicative of a hypoglutamatergic state.
PACSIN 1 was found to be reduced in schizophrenia and is one of a family of cytoplasmic phosphoproteins, which are thought to have a role in synaptic vesicle formation and transport and more generally in recruiting interacting proteins to sites of endocytosis. PACSIN 1 is specifically localized in neurons and has been found to colocalize with dynamin and bind to synaptojanin. 55 Interestingly, DYN-I was significantly increased in schizophrenia in comparison to control patients (P = 0.0055) and is localized to presynaptic nerve terminals in the brain. 56 Additionally, DYN-I has also been found to interact with NMDA receptor 1 57 and SNAP-23, 58 closely related to SNAP-25, proteins which have been previously implicated in the pathogenesis of schizophrenia. [59] [60] [61] [62] DYN-I is a GTPase essential for the recovery of synaptic vesicles from the neuronal membrane once the contents have been released 63 and has been hypothesized to have evolved to have a primary role in synaptic vesicle recycling. 64 ), who found that DYN-I and II were increased in the grey matter but decreased in the white matter of schizophrenics in comparison to controls, while a recent proteomics study of the anterior cingulate cortex in schizophrenia also reported an increase in dynamin 1 in schizophrenia. 32 NF-L is a neuronal-specific intermediate filament protein with a cytoskeletal and synaptic function known to interact with NMDA receptors in the postsynaptic density. We found this protein to be significantly decreased in expression in schizophrenia in comparison with control patients. This is in agreement and further confirms findings reported in a recent paper of reduced NF-L protein expression in the dlPFC in elderly schizophrenic patients. 65 Interestingly, this protein also interacts with 14-3-3 gamma which has been implicated in schizophrenia previously 66, 67 and which also interacts with the disrupted in schizophrenia 1 protein strongly implicated in the disease. 68, 69 Postsynaptic density and glutamatergic system implicated by findings Several proteins that were differentially expressed in this investigation, namely PACSIN, NF-L, DYN-I and septin 5, are involved in the function of the pre-and/ or postsynaptic density, and through these in NMDAregulated glutamatergic neurotransmission, strongly implicated in the pathophysiology of schizophrenia. 70, 71 In addition, many of the susceptibility genes for schizophrenia to date have been shown to play a role in glutamate function. 47 Proteins such as disrupted in schizophrenia 1, SNAP-25, 14-3-3 gamma, synaptojanin 1, complexins I and II and synataxin have all previously been implicated in schizophrenia pathology and are known to directly interact with one or more of the proteins found to have altered expression in this study (see Figure 4) . Alpha internexin is the only protein listed in Figure 4 , which was shown to be selectively altered in bipolar disorder and this protein interestingly has been shown to be involved in NMDA receptor functioning. 57 These findings thus support evidence for glutamatergic dysfunction in mood disorders 72, 73 as well as in schizophrenia. Figure 4 Cartoon illustrating the interactive protein partners of the NMDA receptors 1 and 2, which have previously been implicated in schizophrenia (outlined). Proteins implicated in this study for the first time are underlined. Those proteins implicated previously and also shown to be abnormally expressed in this study are outlined underlined. Alpha internexin was found in bipolar disorder only, all others were found in schizophrenia and/or bipolar disorder. Refer to Table 2 for detailed information on each of the proteins found to be abnormally expressed in this study. Interactive information was obtained from the human protein reference database (www.hprd.org). NMDA, N-methyl-D-aspartate.
Evidence for septin family contribution to schizophrenia and bipolar disorder Five forms of septin 5 present on the 2D gels analysed in this study were significantly increased in expression in bipolar disorder, with three of these significant also in schizophrenia in comparison to controls (see Table 3 ). In addition, two forms of septin 11 and one of septin 6 were found to be significantly increased in bipolar disorder. While the functional roles of the septin family of proteins within the brain are unclear at present, there is a growing literature indicating that they have important, diverse and developmental stage-specific functions within the brain. 74 With regard to schizophrenia, it is of interest that the gene for septin 5 is located in chromosomal region 22q11.2, parts of which are deleted in velo-cardiofacial syndrome and whose sufferers have been found to have a much higher rate of schizophrenia than the general population (30%). 75 A recent molecular examination of the deletion breakpoints in adults with 22q11 deletion syndrome found that the septin 5 gene is located within the region deleted in all the patients suffering this disorder, including all those with schizophrenia (n = 44 in total). 76 While the mechanism by which septin 5 may be involved in the pathogenesis of schizophrenia is unknown, it is clear that there is now intriguing evidence for its involvement. There is an apparent contradiction in a protein with increased expression in schizophrenia (septin 5) being located within a deletion region associated with the disorder. Of interest in this regard is a recent study that describes an increase in the proportion of one form of catechol O-methyltransferase in comparison with total catechol O-methyltransferase protein expression, the gene for which is also located on 22q11, in schizophrenia and bipolar disorder compared to controls 77 -for like septin 5, catechol O-methyltransferase is located in the 22q11 deletion region. In addition, at the mRNA level, previous work by the same group has found no differences in the catechol O-methyltransferase transcript. 77 This work, with our own, indicates that the presence of candidate genes within a deletion region associated with the disorder does not necessarily imply reduced cortical mRNA and protein expression levels within the group of schizophrenic subjects as a whole. Rather, the data suggest that altered expression of these candidate genes are vulnerability factor to disease regardless of the direction of expression changes.
Functionally, septins are GTP-binding proteins often found in association with actin and microtubule filaments, and decreased septin expression has been found to lead to increased microtubule stability. 78 Functionally, it has also been found that septin 5 binds to presynaptic SNARE complex proteins and inhibits exocytosis. 79, 80 Indeed, many septins have been shown to have synaptic-associated binding partners which have been previously implicated in schizophrenia, for example syntaxin, complexin II and the microtubule-associated protein. [78] [79] [80] Septin 5 (also known as CDCrel-1 and Peanut-like 1) appears particularly interesting as it has been previously found to colocalize with GABAergic vesicles. 81 In a study investigating the distribution of septin 5 in the adult human brain, differential centrifugation revealed it to associate predominantly with neurons and to co-purify with SNAP-25 and synaptophysin marked synaptosomes. 82 Further work is needed to evaluate the expression pattern of this protein in the dlPFC in normal human brain.
Little is known about the function of septin 11 as it has only recently been sequenced. It has been found to be highly expressed in the brain along with septins 3, 4, 5, 7 and 8. 74 Septins 2 and 4 have previously been associated with Alzheimer's disease due to their localization in neurofibrillary tangles 83 and septin 5 is a known binding partner of the Parkinson's diseaseassociated protein parkin. 84 In addition, a review of the septin family of proteins and their distribution in mouse brains 81 found that the majority of the septin family were localized around synaptic vesicles near the terminals in unmyelinated axons with the highest expression within the brain seen in the cerebral cortex, hippocampus, cerebellum, thalamus and striatum. These data and the other work discussed previously indicate that members of the septin family of proteins may function in synaptic vesicle transport, fusion or recycling events in the human brain. Abnormalities in the expression of these proteins could contribute in part to the synaptic dysfunction observed in schizophrenia and bipolar disorder.
Evidence for metabolic dysfunction in bipolar disorder and schizophrenia Changes in mitochondrial and metabolic function have been implicated in schizophrenia previously. [31] [32] [33] [85] [86] [87] [88] The results of this study extend this abnormality to bipolar disorder, whereby almost half of all significantly differentially expressed proteins identified were found to have a mitochondrial or other metabolic function. In the schizophrenia group, this figure was a quarter, suggesting that metabolic dysfunction in this area is relatively more prominent in bipolar disorder than schizophrenia. In a previous proteomic study of white and grey matter in the dlPFC in schizophrenia, 50% of differentially expressed identified proteins were found to be altered in this functional group. 31 The finding of abnormal metabolic-associated proteins supports previous work suggesting a 'mitochondrial hypothesis' of the disorder 89 and also previous imaging studies which have found an increased metabolism, for example, 90 in bipolar subjects in comparison with controls. Microarray work has revealed decreases in metabolic-associated transcripts in bipolar disorder. 91, 92 However, decreased metabolic-associated transcripts have been associated with decreased brain pH, 34 a common confounding factor in psychiatric postmortem brain research. Due to this latter finding, it is important to interpret with care the data that is obtained from the Stanley array data set, which is not corrected for brain pH, as the mean values in the schizophrenia and bipolar groups are lower than in the control subjects. In addition to this, and in support of our data, in a sub-group of medicationfree bipolar disorder patients, mitochondrial gene transcripts were shown to be increased in expression in comparison with controls. 93 Some of the findings associated with mitochondrial dysfunction are in agreement with the findings in other psychiatric diseases in a previous proteomic study from our group that focused on the anterior cingulate cortex in a different brain series. 33 Specifically, the increase in ATP synthase beta in bipolar disorder was also found in patients with major depression in the anterior cingulate cortex study, and succinyl CoA ligase and alpha tubulin were found to be increased in bipolar disorder in both studies. Proteins also found to be abnormally expressed in a recent proteomic study of the dlPFC in schizophrenia are D-3 phosphoglycerate dehydrogenase, ubiquinol cytochrome c reductase, peroxiredoxin 2, gamma enolase and aldehyde dehydrogenase. 31 However, in this study, these proteins were all found to be decreased in schizophrenia in comparison to controls, whereas in our study, with the exception of peroxiredoxin 2, we found increases in these proteins in bipolar disorder in comparison to controls. We did observe a decrease (À3.06-fold) in gamma enolase in schizophrenia versus controls, which has also been found previously. 31 This divergence could be interpreted as providing further evidence for differential disease expression of metabolic proteins, with mostly increases observed in bipolar disorder and decreases in schizophrenia. However, it could also be explained by our accounting for the effect of potentially confounding factors such as age and PMI in the statistical analysis, factors that were not taken into consideration in the study by Prabakaran et al. (2004) .
Therefore, this study extends the findings of mitochondrial and metabolic dysfunction in schizophrenia and suggests that there may be greater dysfunction in this area in bipolar disorder. Although these findings are in contrast with a recent microarray study which found no evidence for alterations in the dlPFC, compared to 393 abnormally expressed gene transcripts in the orbitofrontal cortex, 94 this study does support our findings of metabolic dysfunction in bipolar disorder. As proteomic studies act to reveal only potential candidate proteins involved in a disease process, further work examining mitochondrial protein complexes in these disorders is needed to confirm and extend these findings.
Protein to transcript level: comparisons using the Stanley genomics database Tissue from the dlPFC (BA46) from the same samples as those used in this study has been used previously in six microarray studies whose data sets are available through the public online database www.stanleygenomics.org. 95 To investigate how our findings relate to the transcript level data, we carried out parametric t-tests on all the probes that related to our significantly differentially expressed proteins of interest (n = 84) in both the schizophrenia and bipolar disorder groups in comparison with control subjects. More specifically, we chose three of the data sets available on this Stanley Medical Research Institute genomic database (Study IDs; 1, 3 and 7) as these used the HGU133A Affymetrix platform and hence had comparable probes. From these data sets, 29 probes relating to 23 specific proteins were found to be significantly differentially expressed at P < 0.05 in one or more of the studies whose data sets were examined. More details about the proteins we found to be abnormally expressed are given in Table 2 . Of particular interest was the finding of significant alteration of septin 11 in two of the studies in bipolar disorder (1 and 7) and two septin 6 probes in both schizophrenia and bipolar disorder in the Kato data set only. There was also significance seen in one of the septin 5 probes in both schizophrenia and bipolar disorder in the Bahn data set; however, it should be noted that this probe is not specific to septin 5 alone.
In total, 4 of the schizophrenia-associated and 19 of the bipolar-associated proteins in this study were also found to be abnormally expressed at the transcript level in one or both of these disorders in three of the microarray studies carried out on the same tissue. Unfortunately, direction of change of transcript expression could not be calculated directly from the data provided on the website. We were therefore unable to ascertain whether gene and protein expression changes were in the same direction. Nonetheless, given the fact the microarray data sets were not adjusted for covariates, validation of differential expression at the transcript level is encouraging and provides further evidence of abnormalities in these proteins in these disorders.
Methodological issues
In proteomic studies of human post-mortem material it is useful to know what proteins might be altered due to the influence of confounders. Other proteomic study designs range from incorporating almost all covariates (though notably not PMI) into their ANCOVA analysis 30 to none. 31 In the present study we adjusted for age, brain pH, PMI and refrigerator interval with a secondary analysis of the effects of these factors plus alcohol abuse and medication status at time of death on protein expression in the whole-brain series. The results of these analyses suggest that many proteins shown to be altered in expression by disease are also related to some of the confounding factors that exist within these patients (see Table 2 ). Additionally, the importance of accounting for the effects of tissue pH on mRNA expression in microarray work is now acknowledged, 34 indicating that these are important factors to consider when analysing high-throughput data sets.
Some of the findings revealed in this study may appear to contradict previous research, for example an upregulation of glial fibrillary acidic protein (GFAP). 17, 30 More specifically, reduced levels of phosphorylated GFAP have been reported in the PFC and hippocampus, 96 and a downregulation of four forms of GFAP were also reported in another proteomic study of the dlPFC. 30 However, an increased protein expression of GFAP in lamina II, III, IV and VI in BA9 of the dlPFC has also been reported. 97 This previously reported increase in GFAP was found to correlate with antipsychotic intake; however, post hoc analysis of this in our data set did not support this finding (Spearman's rank 0.221). We consider that the reason for the inconsistency of these results may relate to the presence of GFAP on 2D gels as multiple protein spots representing post-translational modifications and/or different isoforms. 98 Nonsignificant trend reductions in other GFAP spots could have been present in the schizophrenia sample. The investigation of the functional states of the proteins (phosphorylation and glycosylation states) found to be abnormally expressed is important to determine the functional relevance of these different findings.
Another issue concerns the use of crude brain tissue in all proteomic studies of psychiatric disorders undertaken to date, including our own. The proteome assessed in such samples is obviously restricted to the proteins that are separated on a 2D gel, and these are often highly abundant with lower molecular weight. Additionally, for a small number of spots, several proteins were identified within them, therefore the quantitative data relating to these are less certain and further work is required to validate these findings (see Table 2 ). In relation to our findings of altered septin expression in schizophrenia and bipolar disorder, we feel that is worth noting the very large number of septin proteins revealed to be abnormal in this study, the consistent direction of this change and the consistency with the microarray data (as discussed above). We consider that this represents robust internal confirmation of these changes. We propose to confirm these finding further using 2D differential in gel electrophoresis in an independent brain series and also using subcellular enrichments for synaptic and membrane-associated proteins.
Conclusions
This human post-mortem proteomic study has revealed many alterations in protein expression in the dlPFC in both schizophrenia and bipolar disorder patients in comparison to controls. Almost half of the proteins found to be abnormally expressed in schizophrenia were found to be synaptic-associated and many of these proteins have functions that involve the presynaptic machinery and NMDA receptor activity. In bipolar disorder, metabolic abnormality was the largest area of cellular dysfunction observed in this study. A particularly interesting insight gained from this study is the involvement of the septin family of proteins in major psychiatric disorders. Based on our present findings, future work will seek to confirm and extend the involvement of septin proteins, and also to characterize more fully the synaptic proteome in these disorders.
